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Abstract
Background: Real-time quantitative RT-PCR (RT-qPCR) is a “gold” standard for measuring steady state mRNA levels
in RNA interference assays. The knockdown of the epidermal growth factor receptor (EGFR) gene with eight
individual EGFR small interfering RNAs (siRNAs) was estimated by RT-qPCR using three different RT-qPCR primer
sets.
Results: Our results indicate that accurate measurement of siRNA efficacy by RT-qPCR requires careful attention for
the selection of the primers used to amplify the target EGFR mRNA.
Conclusions: We conclude that when assessing siRNA efficacy with RT-qPCR, more than one primer set targeting
different regions of the mRNA should be evaluated and at least one of these primer sets should amplify a region
encompassing the siRNA recognition sequence.
Background
RNA interference (RNAi) can mediate a short-term or
prolonged silencing of gene expression at the RNA and
protein level. Knockdown efficiency is typically mea-
sured at the mRNA level by quantitative RT-PCR (RT-
qPCR) or estimated at the protein level by immunoblot,
enzyme-linked immunosorbent assay (ELISA) or immu-
nohistochemistry (IHC) [1]. Many prefer measuring the
relevant protein with immunoblot directly, because pro-
tein knockdown is most relevant to the observable phe-
notype under study. However, in practice, a suitable
antibody to a given target protein may not always be
readily available or will not allow a quantitative estimate
of the magnitude of the effect of RNAi. The long turn-
over time of many proteins may underestimate the
RNAi effect at the mRNA level. A direct measurement
at the mRNA level is therefore often the preferred
method to more directly verify that RNAi is effectively
decreasing the amount of the transcript. Real-time RT-
qPCR is the “gold” standard for measuring steady-state
mRNA levels. Hence, an accurate measurement method
of the mRNA knockdown is needed. There are indica-
tions that mRNAs are not completely degraded after 24
hrs of RNAi exposure [2]. Therefore the location of the
primer might be relevant as some primer sets may
amplify remaining cleavage products, leading to an
underestimation of the RNAi efficacy [3]. Despite this,
numerous publications on RNAi with RT-qPCR do not
evaluate the primers choice. The lack of precise criteria
for choosing the target sequence for RT-qPCR amplifi-
cation is surprising. Here, evidence is presented that the
location of RT-qPCR primers is critical in the evaluation
of the epidermal growth factor receptor (EGFR) small
interfering RNA (siRNA) efficacy, even up to 72 hrs
post-treatment in lung cancer cells.
Results and Discussion
In the present study, we evaluated the RT-qPCR assay
used to measure the siRNA knockdown of EGFR
expression. In our experiments, we were interested in
determining the ability of a series of EGFR siRNAs to
knock down the levels of endogenous EGFR mRNA
expression in a human lung cancer cell line expressing
wild type EGFR. To exclude effects of transfection effi-
ciency on siRNA efficacy, we determined H358 cells
transfection efficiency with two approaches: cell fluores-
cence by siGLO Transfection Indicators and cell death
induced by TOX Transfection Control. The transfection
efficiency was higher than 81% at 48 hrs and 92% at 72
hrs, as accessed by either CellTiter-Blue
® Cell Viability
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microscopy (data not shown). These data suggested that
the transfection efficiency was nearly optimal with all
siRNAs tested. Of the eight siRNAs examined, s604,
s752 and s1247 siRNAs showed the highest efficiency in
the knockdown of the EGFR mRNA (Figure 1B). With
primer sets q1 and q3 initially used, the reduction of
EGFR transcript levels was not greater than 57% at 48
hrs. We then redesigned a primer set q2 to overlap or
encompass the EGFR target site of siRNA s1247. Upon
reexamination with primer set q2, which encompasses
the target site and using siRNA s1247, a 71% decrease
of the EGFR mRNA level was observed. It was the
strongest effect observed for all eight siRNAs tested. In
contrast, the primer set q2 underestimated the knock-
down efficacy in the siRNA s604 and s752 experiments
in comparison to what was measured with primer set q1
for the same siRNAs. This primer set q1 amplifies a
sequence that locates nearer to the target sequence of
s604 and s752. Similar results were observed at 72 hrs:
with primer set q2, a knockdown of 72% was found in
the s1247 experiments, whereas with the same siRNA
q1 detected a 53% knockdown and q3 a 53% knockdown
(Figure 1B).
RT-qPCR amplification of a specific targeted mRNA
sequence reflects the integrity of that fragment, but does
Figure 1 Determination of EGFR siRNA knockdown efficiency in H358 cells with RT-qPCR. (A) Schematic diagram of the EGFR gene exon
(boxes) structure and location of siRNAs and RT-qPCR primer sets. For the siRNAs sequences, see Table 1. For the primers sequences, see
Table 2. Primer sets were named according to the order of the sequences. (B) EGFR mRNA knockdown efficiency detected by RT-qPCR
amplification from EGFR siRNA-treated H358 cells using either the primer set q1,q2 and q3 at 48 hrs (Left), and at 72 hrs (Right). Transfections
were performed in triplicate. The percentages are relative to the mock treated control.
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suggest that the EGFR mRNA fragments amplified by
the q1 or q3 primer sets after transfection of s1247,
remain more intact despite RNA cleavage and thus
result in an overestimation of the amount of remaining
intact target mRNA. The relatively higher knockdown
read-out with primer set q1, after transfection with s604
and s752, compared to q3, is also consistent with this
observation (Figure 1B). These results thus suggest that
s1247 is the most effective of the siRNAs tested.
To further corroborate this hypothesis we analyzed
EGFR protein levels with western blot and studied pos-
sible phenotypic consequences of EGFR down-regulation
in H358 cells. Cell viability and caspase-3/7 activity were
measured and, in addition, we evaluated the induction
of apoptosis. The aggregate results of these experiments
are consistent with the mRNA knock down results
obtained in the RT-qPCR experiments and confirm that
of the siRNAs tested, the s1247 is the most powerful
siRNA on H358 cells to down-regulate the EGFR pro-
tein level, inhibit the cell viability and induce apoptosis
in comparison to other siRNAs (Table 1, Figure 2).
To verify whether the effect of primer set choice on
RT-qPCR results is also observed with other messengers,
we transfected a positive, validated GADPH siRNA
(Invitrogen, proprietary sequence) into H358 cells and
measured the GAPDH mRNA knockdown level with
three different primer sets located in different positions.
With different locations, the primers detected different
knockdown efficiencies (data not shown), and the best
primer set was GAPDH 820F and 1106R (Table 2). The
results from GAPDH RNAi area n a l o g o u st ot h ed a t a
obtained with the EGFR mRNA suggesting that these
findings can be generalized, i.e., measurements of the
knockdown efficiency can be influenced by the primer
set used for RT-qPCR.
SiRNA induced cleavage of mRNA appears to be fol-
lowed by degradation of the messenger, which is
assumed to be complete 24-48 hrs after siRNA treat-
ment [4]. Consequently, the position of the PCR primers
within the mRNA (cDNA) is generally considered irrele-
vant, and many publications do not provide a rationale
for the primers chosen and specifically do not include
qPCR primers that overlap with the siRNA target
sequence. However, there are indications that mRNAs
are incompletely degraded 24 hrs after transfection as
evidenced by others in a Northern blot analysis follow-
ing treatment with siRNAs against coagulation factor III
[2]. Our results corroborate and strengthen observations
made by Shepard et al. [3]. In a study targeting the con-
nective tissue growth factor in human trabecular mesh-
work cells, they found that the location of the qPCR
primers relative to the siRNA target sequence pro-
foundly influenced the RT-qPCR results, by as much as
60%, 24 hrs post-transfection. They also showed that
these results were independent of siRNA concentration,
siRNA:lipid ratio, or transfection efficiency. Primer sets
that did not overlap the siRNA target sequence yielded
a lower knockdown efficiency, which can be explained
by the existence of partially degraded mRNA molecules
that are still detected in the RT-qPCR assay. However
these results favoring a primer position effect were
based upon analysis 24 hrs post treatment, a time point
at which abundant mRNA may have been cleaved by
the argonaute protein, but not yet degraded by exonu-
cleases. More recently, the importance of primer posi-
tion for assessment of MYCN oncogene siRNA silencing
in a human neuroblastoma cell line (IMR-32) was also
described by the group of Vandesompele [5]. Their RT-
qPCR analysis was at 48 h post transfection. Our pre-
sent results strongly suggest that amplification of incom-
pletely degraded mRNA molecules, as observed with the
EGFR q1 and q3 primer sets with siRNA s1247, may
lead to underestimation of the siRNA efficacy, at least
up to 72 hrs post-treatment. Nevertheless, the fact that
these position effects were measureable in different cell
types (trabecular cells, neuroblastoma and lung cancer
cell lines), and with different genes (connective tissue
growth factor, MYCN oncogene, EGFR, GAPDH),
strongly suggests that incomplete degradation of mRNA
following siRNA treatment is a general phenomenon
that may significantly affect RT-qPCR results in RNAi
research.
Conclusions
We thus conclude that there is an unexpected but sig-
nificant interdependence between the EGFR targeting
siRNA sequence and the RT-qPCR amplification region
for assessing the efficacy of the siRNA target gene
knockdown and that this finding can be extended to
other mRNAs in lung cancer cells. We therefore recom-
mend that qPCR primers for siRNA work should span
the putative siRNA cleavage site, thus avoiding the
amplification of mRNA molecules that underwent only
the initial steps of the siRNA induced degradation pro-
cess. It is also recommendable to test more than one
primer set at different locations on the mRNA, particu-
larly for mRNA targets that appear to be refractory to
siRNA-mediated cleavage. Ideally, at least one of the pri-
mer sets should amplify a region encompassing the
siRNA recognition sequence to ensure optimum siRNA
efficacy readout.
Methods
siRNA transfection
Eight siRNAs targeting wild type EGFR sequences were
analyzed (Table 1, Figure 1A). EGFR siRNA604
and EGFR siRNA1247 were from Invitrogen (Ref.
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Page 4 of 8Table 1 Phenotypic consequence of EGFR downregulation by siRNAs
Name of
siRNA
exon sequence Location
a Designed
by
RNA knockdown Measured
with q2 (%)
Protein
downregulation (%)
Viability
(%)
Caspase-3/
7( % )
Apoptotic
cells (%)
Viable cells
(%)
EGFR
siRNA604
3 GCAGTCTTATCTAACTATGATGCAA C.604_628 Invitrogen 19 ± 5 43 ± 3 94 ± 2 170 ± 8 168 ± 6 90 ± 2
EGFR
siRNA752
4 GCAGTGACTTTCTCAGCAA C.752_770 Eurogentec 44 ± 13 28 ± 1 96 ± 2 149 ± 6 137 ± 6 94 ± 1
EGFR
siRNA1247
8-9 GCAAAGTGTGTAACGGAATAGGTAT C.1247_1271 Invitrogen 72 ± 4 51 ± 3 92 ± 0 179 ± 6 177 ± 7 86 ± 2
EGFR
siRNA1608
12 GGAGATAAGTGATGGAGAT C.1608_1626 Eurogentec 25 ± 9 11 ± 1 97 ± 2 132 ± 7 131 ± 6 94 ± 1
EGFR
siRNA2654
20 GGGAACACAAAGACAATAT C.2654_2672 Dharmacon 18 ± 22 1 ± 1 106 ± 1 102 ± 6 104 ± 2 92 ± 1
EGFR
siRNA2708
20-
21
TCGCAAAGGGCATGAACTA C.2708_2726 Dharmacon 21 ± 9 8 ± 1 106 ± 1 141 ± 6 136 ± 6 105 ± 2
EGFR
siRNA3768
28 GGACTTCTTTCCCAAGGAA C.3768_3786 Eurogentec 48 ± 8 2 ± 1 97 ± 2 126 ± 6 125 ± 6 96 ± 1
EGFR
siRNA4765
28 AGAATGTGGAATACCTAAGG C.4766_4785 * 2 ± 7 2 ± 1 108 ± 3 146 ± 6 137 ± 6 93 ± 3
Negative
siRNA
proprietary sequence designed by
Eurogentec
16 ± 11 3 ± 1 111 ± 2 97 ± 2 100 ± 2 97 ± 0
Blank
control
1 ± 5 1 ± 0 116 ± 2 107 ± 4 101 ± 1 98 ± 1
aReference sequence identical to NM_005228.3
b Modified from [7].
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8Figure 2 Down-regulation of EGFR protein levels and phenotypic consequences of EGFR knockdown. (A) Western blot was performed to
determine the down-regulation levels of EGFR protein. (B) Cell viability was detected by CellTiter-Blue
® Cell Viability Assay. (C) Caspase-3/7
activity was measured by Apo-ONE
® Homogeneous Caspase-3/7 Assay. (D, E) Viable and apoptotic cells were counted with Hoechst 33342 and
propidium iodide (PI) double fluorescent chromatin staining. The aggregate results are consistent with the mRNA knockdown results obtained in
the RT-qPCR experiments and confirm that of the siRNAs tested, the s1247 is the most powerful siRNA on H358 cells to down-regulate the EGFR
protein level, inhibit the cell viability and induce apoptosis in comparison to other siRNAs (Results see Table 1). Idem as above.
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trogen, Merelbeke, Belgium); the other siRNAs were
synthesized by Eurogentec (Eurogentec S.A., Liege, Bel-
gium). All the sequences used for siRNAs were finally
blasted http://blast.ncbi.nlm.nih.gov/Blast.cgi to avoid
silencing unrelated genes. The glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) positive control siRNA
was from Invitrogen (ref. SKU#12935-140 Stealth RNAi
GAPDH Positive Control, Invitrogen Merelbeke, Bel-
gium). Eurogentec provided the negative control siRNA
(OR-0030-neg 05, Eurogentec S.A., Liege, Belgium), a pro-
prietary siRNA sequence that does not correspond to
any human gene. TOX Transfection Control and siGLO
Green Transfection Indicators were ordered from
Thermo Scientific Dharmacon (ref. D-001630-01-02; D-
001500-01-05, Thermo Scientific Dharmacon, Blenheim,
England). The human non-small cell lung cancer
(NSCLC) cell line NCI-H358, wild type for EGFR, was
obtained from the American Type Culture Collection
(ATCC, Netherlands) and cultured in RPMI 1640 med-
ium (Invitrogen Corp., Gent, Belgium), supplemented
with 10% heat-inactivated fetal bovine serum (Perbio
Science NV, Erembodegem, Belgium), 2 mM L-glutamine
and 1 mM sodium pyruvate at 37°C in a humidified
incubator with 5% CO2 but without penicillin or strep-
tomycin, which will otherwise cause cell death during
lipofectamine transfection. Cell line H358 was trans-
fected with EGFR siRNAs, a negative control siRNA or
positive GAPDH control siRNA at 40 nM using 1.5 μl
Lipofectamine 2000 (Invitrogen Merelbeke, Belgium)p e r
well in a 24-well format in triplicate.
RNA extraction and LightCycler real time PCR
The EGFR mRNA level was determined 48 hrs and 72
hrs post-transfection by RT-qPCR. Total cellular RNA
isolation was performed on the ABI PRISM 6100 pre-
pstation using the AbsoluteRNA Solution (Applied
Biosystems, Lennik, Belgium) to remove contaminating
DNA and PCR inhibitory substances. RNA concentra-
tions were determined using a ND-1000 NanoDrop
(Thermo Fisher Scientific, Wilmington, Delaware USA),
and used for normalization of the input RNA in the RT-
qPCR. Two hundred nanogram of cellular RNA was
converted to cDNA with a specific reverse primer
(sequences see Table 2) using Moloney Murine Leuke-
mia Virus (MMLV) Reverse Transcriptase (RT-RTCK-
03, Eurogentec S.A., Liege, Belgium) in a total volume of
10 μl. The reverse transcription step was performed on
an Applied Biosystems Thermocycler at 25°C for
10 minutes for the initial step, 30 minutes at 48°C for
the reverse transcription step and 95°C for 5 minutes to
inactivate the reverse transcription enzyme. Oligonu-
cleotide primers (purchased from Eurogentec S.A., Liege,
Belgium) for EGFR were based upon GenBank sequence
(ENSEMBL sequence: ENST00000275493, identical to
NM_005228.3)a n df o rG A P D H ,Ensembl sequence:
ENSG00000111640, identical to NM_002046.3 ). The
primers were designed using the Roche LightCycler
Probe Design Software v1.0 (Idaho Technology, Salt
Lake City, UT), FastPCR (Version 5.4 for Windows), fol-
lowed by BLAST analysis http://blast.ncbi.nlm.nih.gov/
Blast.cgi. Several transcript-specific primer sets were
designed to be located in different exons or spanning an
exon-exon border to avoid amplification of genomic
DNA (Table 2). RT-qPCR analysis was carried out on a
LightCycler 1.5 using the Faststart DNA master SYBR
green mastermix, and with three different primer sets
(Table 2, Figure 1A). The quality of the amplified frag-
ments was monitored using melting curve analysis and
agarose-gel-electrophoresis. Quantitative values were
obtained from the PCR quantification cycle number
(Cq) at which point the increase in signal for the PCR
product was exponential. The target mRNA abundance
in each sample was normalized to its GAPDH mRNA
Table 2 Primer Sequences for EGFR and GAPDH Transcripts used for Real-Time Quantitative reverse Transcriptase
Polymerase Chain Reaction
Name Forward exon Sequence Location
a Reverse
b exon Sequence LocationΔ Length
(bp)
q1 EGFR 370F 2 GGCACTTTTGAAGATCATTTTCTC c.370_393 EGFR 514R 3 CTGTGTTGAGGGCAATGAG c.514_532 163
q2 EGFR
1089F
7 CGAGGGCAAATACAGCTT c.1089_1106 EGFR
1263R
9 AAATTCACCAATACCTATT c.1263_1281 193
q3 EGFR
2034F
15 GGCAGGAGTCATGGGAGAA c.2034_2052 EGFR
2168R
17 GCGATGGACGGGATCTTAG c.2168_2186 153
GAPDH
240F
3 TTGCCATCAATGACCCCTTCA c.240_260 GAPDH
395R
5 CGCCCCACTTGATTTTGGA c.395_413 173
GAPDH GAPDH
820F
8 TGAACGGGAAGCTCACTGG c.820_837 GAPDH
1106R
9 TCCACCACCCTGTTGCTGTA c.1106_1125 306
GAPDH
1016F
8 ACCCACTCCTCCACCTTTG c.1016_1034 GAPDH
1175R
9 CTCTTGTGCTCTTGCTGGG c.1175_1193 177
aReference sequence: EGFR NM 005228.3, GAPDH NM 002046.3.
bThe reverse primers were also used to initiate cDNA synthesis.
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defined as the difference with a mock tranfected control.
Experiments were performed in triplicate. The knock-
down ratio of EGFR RNA expression was calculated
with the formula: (1-1/2
ΔΔCq) × 100% [6].
Protein, viability and apoptosis experiments
Protein down regulation was analyzed by western blot
with a primary antibody against EGFR (1:1000 dilution,
Anti-EGFR, non-phospho-Tyr1173, clone 20G3, Millipore
mouse monoclonal IgG1К, Catalog # 05-484, Lot # 30267,
Bio-connect, Huissen, The Netherlands). The inhibition
ratio of EGFR protein expression was calculated with
the following formula: inhibition ratio of EGFR protein
expression = (1 - the relative intensity of EGFR expres-
sion in the siRNA experiment group/the relative inten-
sity of EGFR in the mock control group) × 100.
Cell viability was determined with the CellTiter-Blue
®
Cell Viability Assay (G8080, Promega, Madison, USA).
The calculation of results was as: fluorescence of
siRNA/mock control × 100. Caspase-3/7 activity was
measured by Apo-ONE
® Homogeneous Caspase-3/7
Assay (G7790, Promega, Madison, USA). Caspase-3/7
activity was measured by fluorescence: assay siRNA/
mock control × 100. The effects of EGFR siRNAs on
apoptosis and nuclear morphology in the cells were
assessed by Hoechst 33342 (Sigma-Aldrich N.V. Bornem,
Belgium) and propidium iodide (PI, Sigma-Aldrich N.V.
Bornem, Belgium) double fluorescent chromatin staining.
Viable, apoptotic and necrotic cells were counted in 10
different fields under a 200 × magnification in each well in
three independent experiments by two persons, and the
average result was compared to the mock control. Values
were presented as the mean ± standard deviation (SD).
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